Roche extends the tender offer for Spark Therapeutics, Inc.’s shares
By Akshay Kedari  Date: 2019-08-01

Roche extends the tender offer for Spark Therapeutics, Inc.’s shares

The extended tender would provide additional time for the U.S. FTC and U.K. CMA to complete their prior disclosed evaluations of Roche’s acquisition of Spark. 

Swiss healthcare giant, Roche Holding AG have recently announced that it has stretched the offering period of its formerly announced tender offer to purchase all the outstanding shares of common stock of U.S. pharmaceutical company, Spark Therapeutics, Inc. for a reasonable price of $114.50 per share.

According to reliable sources, Citibank, N.A., the depository for the offer, had advised Roche that, as of July 30th, around 9,715,086 shares of Spark had been validly tendered and received, leaving an estimated 25.2% of Spark’s shares as outstanding.

Stockholders who have already given their shares of Spark, do not have to re-tender their shares or take any other action as a result of the extension, suggest reports.

Moreover, closing of the tender offer would depend upon customary closing conditions, including the termination of the valid waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Meanwhile, MacKenzie Partners, Inc., information agent for the offer would request for documents, while questions regarding the offer would be diverted to the company.

For the record, Spark Therapeutics is a startup pharmaceutical company that is focused on developing, discovering and delivering gene therapies. The company aims on developing medicines for genetic diseases, including blindness, lysosomal storage disorders, haemophilia and neurodegenerative diseases.

As for Roche, it is focused on progressing science to improve people’s health. The availability of diagnostics and pharmaceuticals under one roof has helped Roche become a leader in personalized healthcare. The company is also a frontrunner in diabetes management and a global leader in vitro diagnostics and tissue-based cancer diagnostics.

Headquartered in Basel, Switzerland, the Roche Group is spread over 100 countries with a workforce of about 94,000 employees recorded last year. Additionally, in 2018, Roche invested a total of CHF 11 billion in R&D and managed to record a sale of CHF $56.8 billion, cite sources.

Source Credit: https://www.globenewswire.com/news-release/2019/07/31/1894176/0/en/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc.html

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Huawei to install new 5G base stations to tackle spreading Coronavirus
Huawei to install new 5G base stations to tackle spreading Coronavirus
By Akshay Kedari

Huawei, the renowned Chinese telecommunications equipment and consumer electronics seller, reportedly announced that it would install new 5G base stations in Wuhan city to help tackle the breakout of Coronavirus. The company has already begun work to...

British officials advise limited role to Huawei in U.K. 5G network
British officials advise limited role to Huawei in U.K. 5G network
By Akshay Kedari

British officials have formally granted Huawei a limited role in the future 5G network of the U.K., dismissing the U.S. calls to completely ban Huawei. The U.S. had earlier accused the company of spying on behalf of the Chinese government.  Off...

Boom and Flight Research to bring XB-1 test flights to Mojave Corridor
Boom and Flight Research to bring XB-1 test flights to Mojave Corridor
By Akshay Kedari

Boom Supersonic, a Colorado based startup that is designing the fastest supersonic airliner in history, has reportedly announced a new strategic partnership deal with Flight Research, Inc., a leading provider of training, services and support activit...

DTM™ spinal cord stimulation shows superior back pain relief in RCT
DTM™ spinal cord stimulation shows superior back pain relief in RCT
By Akshay Kedari

Medtronic plc, a Dublin-based medical technology, services, and solutions company, has reportedly announced three-month results from a large, multicenter RCT (randomized controlled trial) demonstrating statistically meaningful (p=0.0009) and improved...

Mercury Systems, Intel bring in new flight safety-certifiable modules
Mercury Systems, Intel bring in new flight safety-certifiable modules
By Akshay Kedari

Mercury Systems Inc., one of the leading aerospace and defense companies, has recently introduced the first-ever commercially-available compute module, EnsembleSeries™ CIOE-1390 module, embedded with its BuiltSAFE™ technology and Intel&re...